Gossamer Bio, Inc. — Form 8-K
Filed September 9, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Gossamer Bio implemented a 1-for-80 reverse stock split effective September 10, 2026, approved by shareholders on July 14, 2026. The split reduces authorized common shares from 4B to 50M and total authorized capital stock from 4.07B to 120M. The action is designed to regain Nasdaq minimum bid price compliance; all equity awards, warrants, and convertible notes were proportionately adjusted. No cash consideration involved; stockholders' percentage ownership unchanged except for fractional share rounding.
Why this rating
Reverse split is routine capital structure action addressing listing compliance; economically neutral to shareholders. Modest signal of distress but no fundamental business change relative to $271M market cap.
See more from September 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.